Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
复制标题
DOI：
10.1615/critrevoncog.v20.i5-6.100
复制
发表时间：
2015
影响因子：
--
通讯作者：
Pietras R
中科院分区：
文献类型：
--
作者：
Hamilton N;Marquez-Garban D;Mah VH;Elshimali Y;Elashoff D;Garon EB;Vadgama J;Pietras R
三阴性乳腺癌（TNBC）缺乏雌激素受体-α（ERα），孕激素受体（PR）和人表皮生长因子受体-2（HER 2）扩增，几乎占所有乳腺癌死亡的一半。这种乳腺癌亚型主要影响绝经前，非洲裔美国人或具有BRCA 1/2突变的女性。患有TNBC的女性受到更高的远处转移率的困扰，这显着降低了她们的总体生存率和生活质量。由于TNBC患者对化疗的反应较差，他们将从新靶向治疗的开发中显著受益。研究表明，胰岛素样生长因子（IGF）家族和雌激素受体β 1（ERβ1）由于其在代谢和细胞调节中的作用，可能是TNBC管理的有吸引力的目标。在这里，我们回顾了ERβ1和IGF家族在TNBC中作用的科学现状。此外，还强调了二甲双胍治疗TNBC患者的潜在获益以及IGF-ERβ1通路中的治疗潜力领域。
Triple-negative breast cancers (TNBCs) lack estrogen receptor-α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) amplification and account for almost half of all breast cancer deaths. This breast cancer subtype largely affects women who are premenopausal, African-American, or have BRCA1/2 mutations. Women with TNBC are plagued with higher rates of distant metastasis that significantly diminish their overall survival and quality of life. Due to their poor response to chemotherapy, patients with TNBC would significantly benefit from development of new targeted therapeutics. Research suggests that the insulin-like growth factor (IGF) family and estrogen receptor beta-1 (ERβ1), due to their roles in metabolism and cellular regulation, might be attractive targets to pursue for TNBC management. Here, we review the current state of the science addressing the roles of ERβ1 and the IGF family in TNBC. Further, the potential benefit of metformin treatment in patients with TNBC as well as areas of therapeutic potential in the IGF-ERβ1 pathway are highlighted.